---
figid: PMC9187215__nihms-1756839-f0002
figtitle: 'Dysregulation of Type 1 Interferon Signaling in Systemic Sclerosis: a Promising
  Therapeutic Target?'
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC9187215
filename: nihms-1756839-f0002.jpg
figlink: /pmc/articles/PMC9187215/figure/F2/
number: F2
caption: 'Potential druggable targets in the interferon pathway for treatment of systemic
  sclerosis include the following: (I) plasmacytoid dendritic cells; (II) interferon-α/β
  receptor (IFNAR); (III) JAK/STATs; (IV) Interferon regulatory factors (IRF).'
papertitle: 'Dysregulation of Type 1 Interferon Signaling in Systemic Sclerosis: a
  Promising Therapeutic Target?.'
reftext: Minghua Wu, et al. Curr Treatm Opt Rheumatol. ;7(4):349-360.
year: '2023'
doi: 10.1007/s40674-021-00188-9
journal_title: Current treatment options in rheumatology
journal_nlm_ta: Curr Treatm Opt Rheumatol
publisher_name: ''
keywords: Systemic sclerosis | Type I interferon | Treatment
automl_pathway: 0.9006989
figid_alias: PMC9187215__F2
figtype: Figure
redirect_from: /figures/PMC9187215__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9187215__nihms-1756839-f0002.html
  '@type': Dataset
  description: 'Potential druggable targets in the interferon pathway for treatment
    of systemic sclerosis include the following: (I) plasmacytoid dendritic cells;
    (II) interferon-α/β receptor (IFNAR); (III) JAK/STATs; (IV) Interferon regulatory
    factors (IRF).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PDC
  - PNKD
  - PF4
  - IFNA1
  - IFNAR2
  - IFNAR1
  - STAT1
  - JAK1
  - STAT2
  - TYK2
  - IRF5
  - TGFB1
  - TGFB2
  - TGFB3
  - Tofacitinib
  - Ruxolitinib
  - Fibrosis
---
